NZ627259A - Pyran-spirocyclic piperidine amides as modulators of ion channels - Google Patents

Pyran-spirocyclic piperidine amides as modulators of ion channels

Info

Publication number
NZ627259A
NZ627259A NZ627259A NZ62725913A NZ627259A NZ 627259 A NZ627259 A NZ 627259A NZ 627259 A NZ627259 A NZ 627259A NZ 62725913 A NZ62725913 A NZ 62725913A NZ 627259 A NZ627259 A NZ 627259A
Authority
NZ
New Zealand
Prior art keywords
pyran
ion channels
phenyl
modulators
isopropoxy
Prior art date
Application number
NZ627259A
Other languages
English (en)
Inventor
Sara Sabina Hadida-Ruah
Edward Adam Kallel
Vijayalaksmi Arumugam
Mark Thomas Miller
Michael Paul Deninno
Jinglan Zhou
Johnny Uy
Bryan A Frieman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NZ627259A publication Critical patent/NZ627259A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ627259A 2012-01-16 2013-01-15 Pyran-spirocyclic piperidine amides as modulators of ion channels NZ627259A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586875P 2012-01-16 2012-01-16
PCT/US2013/021535 WO2013109521A1 (en) 2012-01-16 2013-01-15 Pyran-spirocyclic piperidine amides as modulators of ion channels

Publications (1)

Publication Number Publication Date
NZ627259A true NZ627259A (en) 2016-12-23

Family

ID=47595110

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ627259A NZ627259A (en) 2012-01-16 2013-01-15 Pyran-spirocyclic piperidine amides as modulators of ion channels

Country Status (10)

Country Link
US (1) US9403839B2 (cg-RX-API-DMAC7.html)
EP (1) EP2804868B1 (cg-RX-API-DMAC7.html)
JP (1) JP6215230B2 (cg-RX-API-DMAC7.html)
CN (1) CN104136442B (cg-RX-API-DMAC7.html)
AU (1) AU2013209958B2 (cg-RX-API-DMAC7.html)
CA (1) CA2863343A1 (cg-RX-API-DMAC7.html)
ES (1) ES2631611T3 (cg-RX-API-DMAC7.html)
MX (1) MX2014008591A (cg-RX-API-DMAC7.html)
NZ (1) NZ627259A (cg-RX-API-DMAC7.html)
WO (1) WO2013109521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918365C (en) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
UA121379C2 (uk) 2013-12-13 2020-05-25 Вертекс Фармасьютикалз Інкорпорейтед Проліки піридонамідів, застосовувані як модулятори натрієвих каналів
JP7104070B2 (ja) 2017-05-16 2022-07-20 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
EP3704114B1 (en) * 2017-11-01 2022-11-23 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
CN108276307A (zh) * 2018-01-17 2018-07-13 常熟浸大科技有限公司 3-氰基-4-烃氧基苯甲酸酯的合成方法
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
CN112689629B (zh) * 2018-07-09 2024-04-23 利伯研究所公司 用于抑制Nav1.8的哒嗪化合物
TWI809427B (zh) 2018-07-13 2023-07-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
SI4069691T1 (sl) 2019-12-06 2025-02-28 Vertex Pharmaceuticals Incorporated Substituirani tetrahidrofurani kot modulatorji natrijevih kanalčkov
EP4347031B1 (en) 2021-06-04 2025-10-29 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US20240285596A1 (en) 2021-06-04 2024-08-29 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
WO2022256679A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CR20240513A (es) 2022-04-22 2025-04-30 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
EP4511114A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN119487003A (zh) 2022-04-22 2025-02-18 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
EP4630405A1 (en) 2022-12-06 2025-10-15 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US121652A (en) 1871-12-05 Improvement in picture-frame hangers
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JPH11512723A (ja) * 1995-09-29 1999-11-02 イーライ リリー アンド カンパニー フィブリノゲン依存血小板凝集抑制物質としてのスピロ化合物
AU2003274053A1 (en) * 2002-10-22 2004-05-13 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
US7576207B2 (en) * 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
MX2010005307A (es) * 2007-11-13 2010-07-28 Vertex Pharma Derivados heterociclicos como moduladores de canales de iones.
JP2011503112A (ja) * 2007-11-13 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物
WO2010002956A2 (en) * 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2010151815A2 (en) * 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
WO2010151595A1 (en) * 2009-06-26 2010-12-29 Schering Corporation Pyrrolo-benzo-1,4-diazines useful as sodium channel blockers
MX2013009393A (es) * 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
ES2618929T3 (es) * 2011-03-14 2017-06-22 Vertex Pharmaceuticals Incorporated Morfolina-Spiro piperidina amida cíclica como moduladores del canal iónico

Also Published As

Publication number Publication date
CN104136442A (zh) 2014-11-05
CN104136442B (zh) 2016-12-21
US9403839B2 (en) 2016-08-02
US20150005304A1 (en) 2015-01-01
WO2013109521A1 (en) 2013-07-25
CA2863343A1 (en) 2013-07-25
MX2014008591A (es) 2014-08-22
JP6215230B2 (ja) 2017-10-18
EP2804868B1 (en) 2017-04-12
AU2013209958B2 (en) 2017-09-07
AU2013209958A1 (en) 2014-08-07
EP2804868A1 (en) 2014-11-26
HK1203074A1 (zh) 2015-10-16
JP2015505321A (ja) 2015-02-19
ES2631611T3 (es) 2017-09-01

Similar Documents

Publication Publication Date Title
NZ627259A (en) Pyran-spirocyclic piperidine amides as modulators of ion channels
MX2013009393A (es) Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
MX347982B (es) Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos.
MX2013008902A (es) Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos.
PH12014502573A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
GEP20207082B (en) Prodrugs of pyridone amides useful as modulators of sodium channels
MY196427A (en) Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors
NZ750187A (en) Pyridone amides as modulators of sodium channels
PH12014501719B1 (en) Pyridone derivatives
TN2015000175A1 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
PH12016500161A1 (en) Thieno[2,3-c]pyrans as cftr modulators
MY176680A (en) Cyclic amides as metap-2 inhibitors
IN2012DE00621A (cg-RX-API-DMAC7.html)
MY178390A (en) Inhibitors of iap
IN2012DE00620A (cg-RX-API-DMAC7.html)
MX2015010611A (es) Nuevos derivados de dihidroquinolin-2-ona como inhibidores de la aldosterona-sintasa (citocromo p450, familia 11, subfamilia b, polipeptido 2 (cyp11b2) o citocromo p450, familia 11, subfamilia b, polipeptido 1 (cyp11b1)).
PH12015501146A1 (en) Hydantoin derivative
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
NZ711328A (en) A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
NZ707087A (en) Novel flavonoid compounds and uses thereof
MX355654B (es) Derivado de paroxetina.
MX2014002343A (es) Inhibidores de parp.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3155030, VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MASSACHUSETTS 02210, US

Effective date: 20150127

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JAN 2020 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20170505

LAPS Patent lapsed